Medigene AG Sustainability Profile
Medigene AG, a pioneering biotechnology company headquartered in Germany, focuses on the development of innovative immunotherapies for cancer treatment. Founded in 1997, Medigene has established itself as a leader in the field, particularly in the areas of T cell immunotherapy and personalised medicine. With a strong operational presence in Europe and North America, the company is renowned for its unique core products, including its proprietary T cell receptor (TCR) technology, which enables the targeting of specific cancer cells. Medigene's commitment to advancing cancer therapies has led to significant milestones, including successful clinical trials and strategic partnerships that enhance its market position. As a result, Medigene AG continues to be at the forefront of the biopharmaceutical industry, driving innovation in cancer treatment.
DitchCarbon Score
How does Medigene AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medigene AG's score of 24 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medigene AG's reported carbon emissions
In 2023, Medigene AG reported total carbon emissions of approximately 458,590 kg CO2e, a decrease from about 492,850 kg CO2e in 2022. The emissions are categorised entirely under Scope 1, with no reported emissions for Scope 2 or Scope 3. This indicates that Medigene's direct emissions from owned or controlled sources are being monitored, while indirect emissions from purchased electricity and other upstream or downstream activities have not been disclosed. Despite the reduction in emissions, Medigene AG has not set specific reduction targets or initiatives, nor are there any commitments to industry-standard climate pledges such as the Science Based Targets initiative (SBTi). The absence of such targets suggests that while the company is actively tracking its emissions, it may not yet be engaging in broader climate commitments or reduction strategies. Overall, Medigene AG's emissions data reflects a focus on direct emissions management, with potential for future climate commitments to enhance its sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 492,850 | 000,000 |
| Scope 2 | - | - |
| Scope 3 | - | - |
How Carbon Intensive is Medigene AG's Industry?
How Carbon Intensive is Medigene AG's Location?
Medigene AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Medigene AG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
